NeuroOne Medical Technologies (NASDAQ:NMTC) Earns "Sell (E+)" Rating from Weiss Ratings

Key Points

• NeuroOne Medical Technologies (NASDAQ: NMTC) has been given a "sell (E+)" rating by Weiss Ratings, while Wall Street Zen upgraded it to a "hold" rating.
• The company reported earnings of ($0.03) per share for the last quarter, beating analysts' expectations, but fell short on revenue with $1.70 million against an expected $1.82 million.
• Institutional investors now own 16.07% of NeuroOne Medical Technologies' stock, with several acquiring new stakes in the second quarter, highlighting increased interest from larger investors.

NeuroOne Medical Technologies (NASDAQ:NMTC - Get Free Report)'s stock had its "sell (e+)" rating reissued by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Other research analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of NeuroOne Medical Technologies to a "hold" rating in a research note on Friday, October 3rd. Maxim Group began coverage on shares of NeuroOne Medical Technologies in a report on Tuesday, September 9th. They issued a "buy" rating and a $3.00 target price for the company. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $2.23.

NeuroOne Medical Technologies Trading Down 1.9%

NMTC stock opened at $1.04 on Wednesday. The company has a market cap of $52 million, a P/E ratio of -6.93 and a beta of 0.71. The company's 50-day moving average price is $0.84 and its 200 day moving average price is $0.73. NeuroOne Medical Technologies has a 52 week low of $0.40 and a 52 week high of $1.39.

NeuroOne Medical Technologies (NASDAQ:NMTC - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. The company had revenue of $1.70 million during the quarter, compared to analysts' expectations of $1.82 million. NeuroOne Medical Technologies had a negative net margin of 55.44% and a negative return on equity of 163.49%. NeuroOne Medical Technologies has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On NeuroOne Medical Technologies

A number of institutional investors have recently modified their holdings of the company. Sio Capital Management LLC bought a new position in shares of NeuroOne Medical Technologies in the second quarter valued at approximately $2,390,000. XTX Topco Ltd acquired a new stake in shares of NeuroOne Medical Technologies in the second quarter worth $51,000. Warberg Asset Management LLC acquired a new stake in shares of NeuroOne Medical Technologies in the second quarter worth $27,000. Goldman Sachs Group Inc. acquired a new stake in NeuroOne Medical Technologies during the first quarter worth $84,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in NeuroOne Medical Technologies during the first quarter worth $69,000. Institutional investors own 16.07% of the company's stock.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.